Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients with COVID-19 (BIRCH): a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study.
Streinu-Cercel A, Castagna A, Chang SC, Chen YS, Koullias Y, Mozaffarian A, Hyland RH, Humeniuk R, Caro L, Davies S, Rodriguez L, Hedskog C, Chen S, Etchevers K, Behenna-Renton N, Llewellyn J, Osinusi A, Duff F, Barrat Hernández A, McNally D, Simon-Campos JA, Leal FE, Fouche LF, González Del Castillo JM. Streinu-Cercel A, et al. Among authors: llewellyn j. Clin Infect Dis. 2025 Jul 22:ciaf406. doi: 10.1093/cid/ciaf406. Online ahead of print. Clin Infect Dis. 2025. PMID: 40694627
Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies.
Grebely J, Feld JJ, Wyles D, Sulkowski M, Ni L, Llewellyn J, Mir HM, Sajed N, Stamm LM, Hyland RH, McNally J, Brainard DM, Jacobson I, Zeuzem S, Bourlière M, Foster G, Afdhal N, Dore GJ. Grebely J, et al. Among authors: llewellyn j. Open Forum Infect Dis. 2018 Feb 9;5(2):ofy001. doi: 10.1093/ofid/ofy001. eCollection 2018 Feb. Open Forum Infect Dis. 2018. PMID: 29450210 Free PMC article.
Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants.
Humeniuk R, Juneja K, Chen S, Ellis S, Anoshchenko O, Xiao D, Share A, Johnston M, Davies S, DeZure A, Llewellyn J, Osinusi A, Winter H, Girish S, Palaparthy R, Dresser M. Humeniuk R, et al. Among authors: llewellyn j. Clin Transl Sci. 2023 Nov;16(11):2276-2288. doi: 10.1111/cts.13627. Epub 2023 Sep 25. Clin Transl Sci. 2023. PMID: 37688349 Free PMC article. Clinical Trial.
Efficacy and Safety of Remdesivir in People With Impaired Kidney Function Hospitalized for COVID-19 Pneumonia: A Randomized Clinical Trial.
Sise ME, Santos JR, Goldman JD, Tuttle KR, Teixeira JP, Seibert AF, Koullias Y, Llewellyn J, Regan S, Zhao Y, Huang H, Hyland RH, Osinusi A, Winter H, Humeniuk R, Hulter HN, Gottlieb RL, Fusco DN, Birne R, Stancampiano FF, Libertin CR, Small CB, Plate M, McPhail MJ; REDPINE Investigators. Sise ME, et al. Among authors: llewellyn j. Clin Infect Dis. 2024 Nov 22;79(5):1172-1181. doi: 10.1093/cid/ciae333. Clin Infect Dis. 2024. PMID: 38913574 Free PMC article. Clinical Trial.
Pharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy Participants.
Anoshchenko O, Abdelghany M, Lichtman A, Duan R, Chen H, Shaik NA, Peng CC, Yue Q, Subramanian R, Hyland RH, Davies S, Castellanos K, Mak L, Shen G, Xiao D, Caro L, Winter H, Llewellyn J, Humeniuk R. Anoshchenko O, et al. Among authors: llewellyn j. Clin Pharmacol Ther. 2024 Nov;116(5):1231-1239. doi: 10.1002/cpt.3337. Epub 2024 Jun 28. Clin Pharmacol Ther. 2024. PMID: 38940465 Clinical Trial.
Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study.
Ogbuagu O, Goldman JD, Gottlieb RL, Singh U, Shinkai M, Acloque G, Fusco DN, Gonzalez E, Kumar P, Luetkemeyer A, Lichtman A, Mozaffarian A, Koullias Y, Hyland RH, Llewellyn J, Osinusi A, Duff F, Humeniuk R, Caro L, Davies S, Rodriguez L, Hedskog C, Chen S, Etchevers K, Nadig P, Kohli A; OAKTREE Trial Investigators. Ogbuagu O, et al. Among authors: llewellyn j. Lancet Infect Dis. 2025 Dec;25(12):1282-1292. doi: 10.1016/S1473-3099(25)00238-5. Epub 2025 Jul 14. Lancet Infect Dis. 2025. PMID: 40675167 Clinical Trial.
Twelve weeks of ledipasvir/sofosbuvir all-oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials.
Asahina Y, Liu CJ, Gane E, Itoh Y, Kawada N, Ueno Y, Youn J, Wang CY, Llewellyn J, Matsuda T, Gaggar A, Mo H, Dvory-Sobol H, Crans G, Chuang WL, Chen PJ, Enomoto N. Asahina Y, et al. Among authors: llewellyn j. Hepatol Res. 2020 Oct;50(10):1109-1117. doi: 10.1111/hepr.13546. Epub 2020 Aug 11. Hepatol Res. 2020. PMID: 32614468
115 results